Evidence map›Paper›PMID 27707913›Full record

ArticleJournal of diabetes science and technology2017

Need for Outcome Scenario Analysis of Clinical Trials in Diabetes.

Rosa Garcia-Verdugo, Michael Erbach, Oliver Schnell

Abstract read
In one paragraph

Article in Journal of diabetes science and technology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Future Perspective of Diabetic Animal Models.Endocrine, metabolic & immune disorders drug targets · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rosa Garcia-Verdugo1 Sciarc Institute, Baierbrunn, Germany.
Michael Erbach1 Sciarc Institute, Baierbrunn, Germany.
Oliver Schnell1 Sciarc Institute, Baierbrunn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the FDA requirement for cardiovascular safety of all new antihyperglycemic drugs to enter the market, the number and extent of phase 3 clinical trials has markedly increased. Unexpected trial results imply an enormous economic, personal and time cost and has deleterious effects over R&D. To prevent unforeseen developments in clinical trials, we recommend performing a comprehensive prospective outcome scenario analysis before launching the trial. In this commentary, we discuss the most important factors to take in consideration for prediction of clinical trial outcome scenarios and propose a theoretical model for decision making.

Indexed as

Clinical Trials, Phase III as TopicDiabetes MellitusHumansHypoglycemic AgentsOutcome and Process Assessment, Health CareResearch DesignTreatment OutcomeHypoglycemic Agentsclinical trialsoutcome predictionscenario analysis

Identifiers

PMID27707913
PMCPMC5478029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.